Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Topical AK, non-melanoma cancer options show promise
Newport Beach, Calif. — When it comes to potential topical treatments for actinic keratoses (AKs) and non-melanoma skin cancers, T4N5 liposome lotion (Dimericine, Applied Genetics Inc. Dermatics) leads the pack. The product is composed of the protein T4 endonuclease V in a liposome vehicle.
Related Videos
Related Content
